The Pioneer of Taiwan Stem cell R&D development, Meridigen Biotech, focused on China market: a large population database. Jointly promote the development of stem cell technology and industrial development with Shanghai Jiaotong University School of Medicine, the owner 14 hospitals. This is a significant cross-strait joint between Jiao-Tong University and NCTU. The strategy will accelerate cross-strait mutual recognition of standards and regulations, in order to build up a stem cells banking society for Chinese.

Three parties, including the chairman of Trans Regional Biotechnology Association, Mr. John Hsuan from Meridigen Biotech, and the vice president of Shanghai Jiaotong University school of Medicine signed a Memorandum of Understanding on 2015 Shanghai-Taiwan Forum. Aim to develop stem cell technology research, promoting cross-strait industry cooperation platform, clinical research along with research services.

Published in Want China Times